Free Trial

Curaleaf (OTCMKTS:CURLF) Trading Down 3.5% - Should You Sell?

Curaleaf logo with Medical background

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s stock price was down 3.5% on Friday . The company traded as low as $0.78 and last traded at $0.80. Approximately 362,163 shares were traded during trading, a decline of 10% from the average daily volume of 402,714 shares. The stock had previously closed at $0.83.

Curaleaf Stock Performance

The company's fifty day moving average is $0.87 and its 200 day moving average is $1.12. The company has a market capitalization of $531.37 million, a P/E ratio of -2.58 and a beta of 0.59. The company has a current ratio of 1.41, a quick ratio of 0.70 and a debt-to-equity ratio of 1.08.

Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). Curaleaf had a negative return on equity of 14.12% and a negative net margin of 17.37%. As a group, equities analysts anticipate that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.

About Curaleaf

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA: Another 200% Growth Ahead? (PLUS 2 Companies Riding Along)
3 Rising Stocks You’ll Want on Your Watchlist
Trillions in Defense Spending—3 Disruptive Stocks Set to Double

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines